Q BioMed Inc announced it has engaged EVERSANA, the pioneer of next-generation commercial services to the global life sciences industry, to immediately support the commercialization of Strontium89.
Strontium89 (Strontium Chloride Sr-89 Injection, USP) is the only US Food and Drug Administration-approved radiotherapy currently available in the US indicated for metastatic cancer bone palliation.
To support and accelerate the product's rollout in the US, Q BioMed said it will leverage the EVERSANA COMPLETE Commercialization model which fully integrates services for market access, agency services, clinical and commercial field teams, health economics, and outcomes in research and compliance. Each service is optimized by data and predictive analytics.
READ: Q BioMed raises $2M with plans for uplisting on NASDAQ; updates on activity for coming months
"We are pleased to have a partner like EVERSANA leading our commercialization efforts going forward, and I believe this adds tremendous value to what we had already established," said Q BioMed CEO Denis Corin in a statement. "The team is passionate about obtaining deep insights into the patient journey and using this knowledge to shape the strategic and creative process needed to maximize commercial successes."
Jim Lang, CEO of EVERSANA, added: "Millions of patients are bearing the burden of devasting pain. We are immediately activating our commercial model to create more awareness, faster access and optimized product support for Strontium89 and its potential to change lives."
In a pivotal trial, as many as 79% of patients found pain relief with Strontium89, and twice as many patients treated with Strontium89 had no pain for three months compared with a placebo.
Furthermore, new pain sites were less frequent in patients treated with Strontium89, which is administered once every three months via injection, and patients can be re-treated if needed.
The ready-to-deploy commercial platform is complemented by more than 5,500 EVERSANA employees and a dedicated commercialization leadership team, replacing Kristin Keller who is leaving Q BioMed. The EVERSANA field force and commercial team will augment an in-place contract sales force focused on the US Department of Veterans Affairs (VA) and Department of Defense (DoD).
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham